<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>17</Volume>
				<Issue>10</Issue>
				<PubDate PubStatus="epublish">
					<Year>2016</Year>
					<Month>10</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Survival Rate of Breast Cancer in Iran: A Meta-Analysis</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>4615</FirstPage>
			<LastPage>4621</LastPage>
			<ELocationID EIdType="pii">40498</ELocationID>
			
<ELocationID EIdType="doi">10.22034/APJCP.2016.17.10.4615</ELocationID>
			
			<Language>EN</Language>
<AuthorList>
<Author>
					<FirstName>Ghasem </FirstName>
					<LastName>Abedi</LastName>
<Affiliation>Health Sciences Research Center, Mazandaran University of Medical Sciences, Sari.</Affiliation>

</Author>
<Author>
					<FirstName>Ghasem </FirstName>
					<LastName>Janbabai</LastName>
<Affiliation></Affiliation>

</Author>
<Author>
					<FirstName>Mahmood </FirstName>
					<LastName>Moosazadeh</LastName>
<Affiliation></Affiliation>

</Author>
<Author>
					<FirstName>Fereshte </FirstName>
					<LastName>Farshidi</LastName>
<Affiliation></Affiliation>

</Author>
<Author>
					<FirstName>Mohammad </FirstName>
					<LastName>Amiri</LastName>
<Affiliation></Affiliation>
<Identifier Source="ORCID">0000-0003-2151-8530</Identifier>

</Author>
<Author>
					<FirstName>Ahmad </FirstName>
					<LastName>Khosravi</LastName>
<Affiliation></Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2016</Year>
					<Month>11</Month>
					<Day>27</Day>
				</PubDate>
			</History>
		<Abstract> &lt;br /&gt; &lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Background: &lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;There has not been a general estimation about survival rates of breast cancer cases in Iran. Therefore, the present study aimed to assess survival using a meta-analysis. &lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Materials and Methods: &lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;International credible databases such as Scopus, Web of Science, PubMed, Science direct and Google Scholar and Iranian databases such as Magiran, Irandoc and SID, from 1997 to 2015 were searched. All articles covering survival rate of breast cancer were entered into the study without any limits. Quality assessment of the articles and data extraction were performed by two researchers using the modified STROBE checklist, which includes 12 questions. Articles with scores greater than 8 were included in the analysis. A limitation of this meta-analysis was different methods for presenting of results in the papers surveyed. &lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Results: &lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;A total of 21 articles with a sample of 12,195 people were analyzed. The one-year, three-year, five-year and ten-year survival rates of breast cancer in Iran were estimated to be 95.8% (94.6-97.0), 82.4% (79.0-85.8), 69.5% (64.5-74.5), 58.1% (39.6-76.6), respectively. The most important factors affecting survival of breast cancer were age, number of lymph nodes involved, size of the tumor and the stage of the disease. &lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;Conclusion: &lt;/span&gt;&lt;/strong&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Times New Roman,Times New Roman; font-size: small;&quot;&gt;The five- and ten- year survival rates in Iran are lower than in developed countries. Conducting breast cancer screening plan support (including regular clinical examination, mammography), public training and raising awareness should be helpful in facilitating early diagnosis and increasing survival rates for Iranian women. &lt;/span&gt;&lt;/span&gt;</Abstract>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_40498_7071b3b17eab9fb80e6a225f658cf9f5.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
